NCT06483386View on ClinicalTrials.gov

Pyrotinib and Subcutaneous Preparation of Trastuzumab Combined With Capecitabine Neoadjuvant Therapy for HER2+ Study of Breast Cancer

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

109

Participants

Timeline

Start Date

July 15, 2024

Primary Completion Date

June 30, 2026

Study Completion Date

December 30, 2026

Conditions
Breast Cancer
Interventions
DRUG

Pyrotinib and Subcutaneous preparation of trastuzumab combined with capecitabine

Pyrotinib and Subcutaneous preparation of trastuzumab combined with capecitabine

All Listed Sponsors
lead

Tianjin Medical University Cancer Institute and Hospital

OTHER

NCT06483386 - Pyrotinib and Subcutaneous Preparation of Trastuzumab Combined With Capecitabine Neoadjuvant Therapy for HER2+ Study of Breast Cancer | Biotech Hunter | Biotech Hunter